Company Encyclopedia
View More
name
Addex Therapeutics
ADXN.US
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder.
4.599 T
ADXN.USMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking160/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-72.84%E
    • Profit Margin-3845.76%E
    • Gross Margin-360.33%E
  • Growth ScoreE
    • Revenue YoY-70.92%E
    • Net Profit YoY-216.40%E
    • Total Assets YoY-36.49%E
    • Net Assets YoY-43.22%E
  • Cash ScoreE
    • Cash Flow Margin-2.60%D
    • OCF YoY-70.92%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreA
    • Gearing Ratio18.72%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Addex Therapeutics Amends ATM Agreement to Boost Capital

    Addex Therapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co., LLC to increase the maximum number of ordinary shares issuable, with an aggregate offering price of up to $3.3 million. This move aims to enhance the company's financial flexibility and strengthen its market position, potentially impacting its operations and investor confidence. Addex Therapeutics focuses on developing therapies for neurological disorders.

    Tip Ranks·
    US
    ADXN
    0.00%
    Tip Ranks·
    US
    ADXN
    0.00%

    Addex Therapeutics Ltd. Q3 2025 shareholders' equity drops 54% to CHF 6.0 million

    Addex Therapeutics Ltd. reported a 54% drop in shareholders' equity to CHF 6.0 million for Q3 2025. Income for the nine-month period fell 62% to CHF 0.2 million, mainly due to the end of an R&D collaboration with Indivior. Operating loss for the period was CHF 2.0 million, a 12% improvement. Cash reserves decreased by 35% to CHF 2.2 million. Net loss per share was CHF 0.05, compared to a profit of CHF 0.08 in 2024.

    Reuters·
    US
    ADXN
    0.00%
    Reuters·
    US
    ADXN
    0.00%

    Swiss stocks - Factors to watch on December 4

    Here are some of the main factors that may affect Swiss stocks on Thursday:ADDEX THERAPEUTICS Third-quarter results due.ANALYSTS' VIEWSTEMENOS AG - JP Morgan raises target price to CHF 90 from CHF 85ECONOMY* Swiss November unemployment rate due at 0800 GMT. Adjusted figure seen at 3.0%.* Swiss November Manufacturing PMI due at 0830 GMT. Seen at 48.5.

    Reuters·
    US
    ADXN
    0.00%
    Reuters·
    US
    ADXN
    0.00%

    Addex Therapeutics Ltd. to Report Third Quarter Financial Results and Host Conference Call

    Addex Therapeutics Ltd. will announce its Q3 2025 financial results on December 4, 2025. CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will provide a business update and product pipeline review during a teleconference and webcast at 16:00 CET. Registration is available for the webcast and conference call. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ADXN
    0.00%
    Reuters·
    US
    ADXN
    0.00%

    Swiss stocks - Factors to watch on December 1

    Swiss stocks to watch on December 1 include Baloise Holding AG's delisting from SIX Swiss exchange on December 8, Swatch Group facing governance reform proposals, Addex Therapeutics' Q3 results, JP Morgan's target price increases for Kuehne+Nagel and VAT Group AG, and key economic indicators like Swiss retail sales, manufacturing PMI, and SNB sight deposits.

    Reuters·
    US
    ADXN
    0.00%
    Reuters·
    US
    ADXN
    0.00%
    © 2025 Longbridge｜Disclaimer